Effect of Recombinant Human Erythropoietin on Serum Nitric Oxide Contents in Patients on maintenance Hemodiaiysis
Wang Caili, Qiao Qing, Zhi Shengli Division of Nepheology, The First Affiliated of Baotou Medical College, Baotou (014010)
Objective To investigate the effect of recombinant human erythropoietin(rhuEpo) on the serumnitric oxide(NO) content in patients on maintenance hemodialysis. Methods Eighty patients on chronic dialysis were divided into two groups: 43 received rhuEpo (HDepo) and 37 did not (HD). Each group consisted of two sub-groups: HDepo-1, with hypertension, n=23; HDepo-2, without hypertension, n=19; HD-1, with hypertension, n=19 and HD-2, without hyperteusion, n=18. Twenty uremic patients without hemodialysis, twenty patients with essential hypertension and 34 normal adult were chosen for control study. Serum content of NO was measured with RIA in all these subjects. Results Serum contents of NO in uremic patients without bemodialysis were significantly higher than those in the 34 normal controls ( p 0 001). Serum NO contents in patients with dialysis were still higher than those in controls ( p 0 001), but were lower than those in patients without dialysis ( p 0 05). The NO contents in dialysed patients after rhuEpo therapy for three months were significantly lower than those in patients before dialysis and in controls ( p 0 001, p 0 05 respectively). Moreover, the diastolic pressure systolic pressure and mean arterial pressure in patients of HDepo group were all significantly higher than those in patients of HD group ( p 0 001), the rising of blood pressure being correlated to the lowering of serum NO content. Conclusion Erythropoietin treatment can reduce the serum NO content in chronic uremic patient on dialysis. Hypertension caused by rhuEpo is related to the lowering of the NO content.